Sellas' experimental blood cancer immunotherapy succeeds in clinical trial
Sellas Life Sciences reports that its experimental immunotherapy, galinpepimut-S, reduced the risk of death by 41% compared to standard treatment in a Phase 3 study for advanced acute myeloid leukemia. This unexpected positive result met the primary goal of the trial, reversing prior skepticism from industry analysts.

Original image temporarily unavailable
According to Sellas Life Sciences, its experimental blood cancer immunotherapy drug called galinpepimut-S achieved the main goal in a Phase 3 clinical trial. The treatment successfully reduced the risk of death by 41% compared with standard care for patients suffering from an advanced stage of acute myeloid leukemia, a type of blood cancer.
This outcome comes as a surprise to industry observers. Previously, biotech columnists and analysts had publicly predicted that the long-delayed study would end in failure and fail to prolong patient survival. The company's latest announcement marks a notable turn of events for the experimental therapy.
View selection rationale
Importance 77/100
About this brief
- Content type
- News summary
- Source type
- Publisher report
- Original source
- STAT Biotech ↗
- Source published
- Process
- AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
- Verification
- The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
- Published by
- Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
- Conflict disclosure
- No financial or commercial conflict declared.
